Jonna K Van Vulpen1, Miranda J Velthuis, Charlotte N Steins Bisschop, Noémie Travier, Bram J W Van Den Buijs, Frank J G Backx, Maartje Los, Frans L G Erdkamp, Haiko J Bloemendal, Miriam Koopman, Marnix A J De Roos, Marlies J Verhaar, Daan Ten Bokkel-Huinink, Elsken Van Der Wall, Petra H M Peeters, Anne M May. 1. 1Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, THE NETHERLANDS; 2Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, THE NETHERLANDS; 3Unit of Nutrition and Cancer, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, SPAIN; 4Department of Clinical Sciences, University of Barcelona, Barcelona, SPAIN; 5Department of Rehabilitation, Nursing Science and Sport, University Medical Center Utrecht, Utrecht, THE NETHERLANDS; 6Department of Medical Oncology, St. Antonius Hospital, Nieuwegein, THE NETHERLANDS; 7Department of Internal Medicine-Medical Oncology, Orbis Medical Center, Sittard-Geleen, THE NETHERLANDS; 8Department of Internal Medicine, Meander Medical Center, Amersfoort, THE NETHERLANDS; 9Department of Medical Oncology, University Medical Center Utrecht, Utrecht, THE NETHERLANDS; 10Department of Surgery, Rivierenland Hospital, Tiel, THE NETHERLANDS; 11Department of Internal Medicine, Hofpoort Hospital, Woerden, THE NETHERLANDS; 12Department of Internal Medicine, Diakonessenhuis, Utrecht, THE NETHERLANDS; and 13Cancer Center, University Medical Center Utrecht, Utrecht, THE NETHERLANDS.
Abstract
PURPOSE: Fatigue is a common problem among colon cancer patients and typically increases during chemotherapy. Exercise during chemotherapy might have beneficial effects on fatigue. To investigate the short- and long-term effects of an exercise program in colon cancer patients during adjuvant treatment, the Physical Activity During Cancer Treatment study was conducted. METHODS: In this multicenter randomized controlled trial, 33 colon cancer patients undergoing chemotherapy (21 men and 12 women) were randomly assigned to either a group receiving an 18-wk supervised exercise program (n = 17) or to usual care (n = 16). The primary outcome was fatigue as measured by the Multidimensional Fatigue Inventory and the Fatigue Quality List. Secondary outcomes were quality of life, physical fitness, anxiety, depression, body weight, and chemotherapy completion rate. Outcome assessment took place at baseline, postintervention (18 wk) and at 36 wk. RESULTS: Intention-to-treat mixed linear model analyses showed that patients in the intervention group experienced significantly less physical fatigue at 18 wk and general fatigue at 36 wk (mean between group differences, -3.2; 95% confidence interval [CI], -6.2 to -0.2; effect size [ES], -0.9 and -2.7; 95% CI, -5.2 to -0.1; ES, -0.8, respectively), and reported higher physical functioning (12.3; 95% CI, 3.3-21.4; ES, 1.0) compared with patients in the usual care group. CONCLUSION: The Physical Activity During Cancer Treatment trial shows that an 18-wk supervised exercise program in colon cancer patients duringchemotherapy is safe and feasible. The intervention significantly reduced physical fatigue at 18 wk and general fatigue at 36 wk. Considering the number of patients included in the present study, replication in a larger study population is required.
RCT Entities:
PURPOSE: Fatigue is a common problem among colon cancerpatients and typically increases during chemotherapy. Exercise during chemotherapy might have beneficial effects on fatigue. To investigate the short- and long-term effects of an exercise program in colon cancerpatients during adjuvant treatment, the Physical Activity During Cancer Treatment study was conducted. METHODS: In this multicenter randomized controlled trial, 33 colon cancerpatients undergoing chemotherapy (21 men and 12 women) were randomly assigned to either a group receiving an 18-wk supervised exercise program (n = 17) or to usual care (n = 16). The primary outcome was fatigue as measured by the Multidimensional Fatigue Inventory and the Fatigue Quality List. Secondary outcomes were quality of life, physical fitness, anxiety, depression, body weight, and chemotherapy completion rate. Outcome assessment took place at baseline, postintervention (18 wk) and at 36 wk. RESULTS: Intention-to-treat mixed linear model analyses showed that patients in the intervention group experienced significantly less physical fatigue at 18 wk and general fatigue at 36 wk (mean between group differences, -3.2; 95% confidence interval [CI], -6.2 to -0.2; effect size [ES], -0.9 and -2.7; 95% CI, -5.2 to -0.1; ES, -0.8, respectively), and reported higher physical functioning (12.3; 95% CI, 3.3-21.4; ES, 1.0) compared with patients in the usual care group. CONCLUSION: The Physical Activity During Cancer Treatment trial shows that an 18-wk supervised exercise program in colon cancerpatients during chemotherapy is safe and feasible. The intervention significantly reduced physical fatigue at 18 wk and general fatigue at 36 wk. Considering the number of patients included in the present study, replication in a larger study population is required.
Authors: Hanna van Waart; Martijn M Stuiver; Wim H van Harten; Edwin Geleijn; Marianne de Maaker-Berkhof; Jolanda Schrama; Maud M Geenen; Jetske M Meerum Terwogt; Simone M van den Heiligenberg; Jeannette A J H Hellendoorn-van Vreeswijk; Gabe S Sonke; Neil K Aaronson Journal: Int J Colorectal Dis Date: 2017-11-09 Impact factor: 2.571
Authors: Dorothea Clauss; Christine Tjaden; Thilo Hackert; Lutz Schneider; Cornelia M Ulrich; Joachim Wiskemann; Karen Steindorf Journal: Support Care Cancer Date: 2017-04-17 Impact factor: 3.603
Authors: Deborah K Mayer; Gina Landucci; Lola Awoyinka; Amy K Atwood; Cindy L Carmack; Wendy Demark-Wahnefried; Fiona McTavish; David H Gustafson Journal: J Cancer Surviv Date: 2017-10-09 Impact factor: 4.442
Authors: Laurien M Buffart; Maike G Sweegers; Anne M May; Mai J Chinapaw; Jonna K van Vulpen; Rob U Newton; Daniel A Galvão; Neil K Aaronson; Martijn M Stuiver; Paul B Jacobsen; Irma M Verdonck-de Leeuw; Karen Steindorf; Melinda L Irwin; Sandi Hayes; Kathleen A Griffith; Alejandro Lucia; Fernando Herrero-Roman; Ilse Mesters; Ellen van Weert; Hans Knoop; Martine M Goedendorp; Nanette Mutrie; Amanda J Daley; Alex McConnachie; Martin Bohus; Lene Thorsen; Karl-Heinz Schulz; Camille E Short; Erica L James; Ronald C Plotnikoff; Gill Arbane; Martina E Schmidt; Karin Potthoff; Marc van Beurden; Hester S Oldenburg; Gabe S Sonke; Wim H van Harten; Rachel Garrod; Kathryn H Schmitz; Kerri M Winters-Stone; Miranda J Velthuis; Dennis R Taaffe; Willem van Mechelen; Marie José Kersten; Frans Nollet; Jennifer Wenzel; Joachim Wiskemann; Johannes Brug; Kerry S Courneya Journal: J Natl Cancer Inst Date: 2018-11-01 Impact factor: 13.506
Authors: Bette J Caan; Jeffrey A Meyerhardt; Justin C Brown; Kristin L Campbell; Elizabeth M Cespedes Feliciano; Catherine Lee; Michelle C Ross; Sara Quinney; Charles Quesenberry; Barbara Sternfeld; Kathryn H Schmitz Journal: Contemp Clin Trials Date: 2020-12-07 Impact factor: 2.226
Authors: Pedro Machado; Miguel Morgado; João Raposo; Marco Mendes; Cândida G Silva; Nuno Morais Journal: Support Care Cancer Date: 2022-02-02 Impact factor: 3.603
Authors: Jonna K VAN Vulpen; Maike G Sweegers; Petra H M Peeters; Kerry S Courneya; Robert U Newton; Neil K Aaronson; Paul B Jacobsen; Daniel A Galvão; Mai J Chinapaw; Karen Steindorf; Melinda L Irwin; Martijn M Stuiver; Sandi Hayes; Kathleen A Griffith; Ilse Mesters; Hans Knoop; Martine M Goedendorp; Nanette Mutrie; Amanda J Daley; Alex McConnachie; Martin Bohus; Lene Thorsen; Karl-Heinz Schulz; Camille E Short; Erica L James; Ronald C Plotnikoff; Martina E Schmidt; Cornelia M Ulrich; Marc VAN Beurden; Hester S Oldenburg; Gabe S Sonke; Wim H VAN Harten; Kathryn H Schmitz; Kerri M Winters-Stone; Miranda J Velthuis; Dennis R Taaffe; Willem VAN Mechelen; Marie José Kersten; Frans Nollet; Jennifer Wenzel; Joachim Wiskemann; Irma M Verdonck-DE Leeuw; Johannes Brug; Anne M May; Laurien M Buffart Journal: Med Sci Sports Exerc Date: 2020-02